Hologic Inc.
Hologic CEO to Retire Upon Go-Private Transaction Completion
Summary
Hologic, Inc. announced that its CEO, Stephen P. MacMillan, will retire upon the closing of the company's go-private transaction with Blackstone and TPG, expected on April 7, 2026. All regulatory approvals for the transaction have been received. MacMillan, who has been with the company since 2013, led Hologic through significant growth and a successful response to the COVID pandemic. The company's next CEO will be announced upon transaction closure.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement